142 related articles for article (PubMed ID: 15507874)
1. New target against inflammatory diseases: transglutaminase 2.
Kim SY
Arch Immunol Ther Exp (Warsz); 2004; 52(5):332-7. PubMed ID: 15507874
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia.
Park KC; Chung KC; Kim YS; Lee J; Joh TH; Kim SY
Biochem Biophys Res Commun; 2004 Oct; 323(3):1055-62. PubMed ID: 15381106
[TBL] [Abstract][Full Text] [Related]
3. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
Kim DS; Park KS; Jeong KC; Lee BI; Lee CH; Kim SY
Cancer Lett; 2009 Jan; 273(2):243-9. PubMed ID: 18804908
[TBL] [Abstract][Full Text] [Related]
4. Increase in transglutaminase 2 in idiopathic inflammatory myopathies.
Choi YC; Kim TS; Kim SY
Eur Neurol; 2004; 51(1):10-4. PubMed ID: 14631123
[TBL] [Abstract][Full Text] [Related]
5. Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors.
Case A; Ni J; Yeh LA; Stein RL
Anal Biochem; 2005 Mar; 338(2):237-44. PubMed ID: 15745743
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver.
Elli L; Bergamini CM; Bardella MT; Schuppan D
Dig Liver Dis; 2009 Aug; 41(8):541-50. PubMed ID: 19195940
[TBL] [Abstract][Full Text] [Related]
7. Antisense inhibition of transglutaminase 2 affects development of mouse embryo submandibular gland in organ culture.
Lee SK; Kim YS; Lee SS; Lee YJ; Song IS; Park SC; Chi JG; Chung SI
Arch Oral Biol; 2005 Sep; 50(9):789-98. PubMed ID: 15970210
[TBL] [Abstract][Full Text] [Related]
8. The multifaceted role of transglutaminase in neurodegeneration: review article.
Karpuj M; Steinman L
Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
Case A; Stein RL
Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
[TBL] [Abstract][Full Text] [Related]
10. The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease.
Freitag T; Schulze-Koops H; Niedobitek G; Melino G; Schuppan D
Autoimmun Rev; 2004 Feb; 3(2):13-20. PubMed ID: 15003183
[TBL] [Abstract][Full Text] [Related]
11. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3).
Hitomi K; Ikura K; Maki M
Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 up-regulates transglutaminase two and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation.
Quan G; Choi JY; Lee DS; Lee SC
Arch Dermatol Res; 2005 Aug; 297(2):84-90. PubMed ID: 16044258
[TBL] [Abstract][Full Text] [Related]
13. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
14. Effects of phenyl saligenin phosphate on cell viability and transglutaminase activity in N2a neuroblastoma and HepG2 hepatoma cell lines.
Harris W; Muñoz D; Bonner PL; Hargreaves AJ
Toxicol In Vitro; 2009 Dec; 23(8):1559-63. PubMed ID: 19735718
[TBL] [Abstract][Full Text] [Related]
15. A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.
Sohn J; Chae JB; Lee SY; Kim SY; Kim JG
Korean J Ophthalmol; 2010 Feb; 24(1):29-34. PubMed ID: 20157411
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2 in inflammation.
Kim SY
Front Biosci; 2006 Sep; 11():3026-35. PubMed ID: 16720373
[TBL] [Abstract][Full Text] [Related]
17. Potential of transglutaminase 2 as a therapeutic target.
Caccamo D; Currò M; Ientile R
Expert Opin Ther Targets; 2010 Sep; 14(9):989-1003. PubMed ID: 20670177
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
Siegel M; Khosla C
Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
[TBL] [Abstract][Full Text] [Related]
19. Expression and activity of transglutaminase II in spontaneous tumours of dogs and cats.
Wakshlag JJ; McNeill CJ; Antonyak MA; Boehm JE; Fuji R; Balkman CE; Zgola M; Cerione RA; Page RL
J Comp Pathol; 2006; 134(2-3):202-10. PubMed ID: 16615935
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase inhibitors: a patent review.
Keillor JW; Apperley KY
Expert Opin Ther Pat; 2016; 26(1):49-63. PubMed ID: 26560530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
